Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0831 | 35.0929054054 | 0.2368 | 0.34 | 0.2202 | 1351000 | 0.28080668 | CS |
| 4 | -0.0051 | -1.56923076923 | 0.325 | 0.34 | 0.2202 | 1100875 | 0.27354406 | CS |
| 12 | -1.4101 | -81.5086705202 | 1.73 | 1.96 | 0.2202 | 2821067 | 0.39662469 | CS |
| 26 | -0.9501 | -74.811023622 | 1.27 | 1.97 | 0.2202 | 1655270 | 0.62019119 | CS |
| 52 | -10.4801 | -97.037962963 | 10.8 | 11.26 | 0.2202 | 1483092 | 1.67413368 | CS |
| 156 | -11.9801 | -97.3991869919 | 12.3 | 13.15 | 0.2202 | 815230 | 3.95886926 | CS |
| 260 | -2.0501 | -86.5021097046 | 2.37 | 20.04 | 0.2202 | 1054794 | 4.2259037 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
